Chr t(11;14)(q13;q32)

However, it should be noted that MRD diagnostics for clinical treatment protocols has to be accompanied by regular international quality control rounds to ensure the reproducibility and reliability of the MRD results. This is available by the EuroMRD network ( https://euromrd.org ), a subgroup of ESHLO ( https://eslho.org ).

Overexpression of PAX5 resulted in increased CCND1 expression. These results support the importance of rs9344 G enhancer in increasing CCND1 expression in MM.

P2, N=9, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 9

P2, N=32, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=50 --> 32

P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2024 --> Jun 2024

P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

P1/2, N=33, Recruiting, Han weidong | Trial primary completion date: Dec 2023 --> Dec 2024

P2, N=81, Active, not recruiting, Nordic Lymphoma Group | Recruiting --> Active, not recruiting

P2, N=124, Active, not recruiting, Acerta Pharma BV | Trial completion date: Dec 2025 --> Sep 2026

P2, N=100, Recruiting, Academic and Community Cancer Research United | Not yet recruiting --> Recruiting

P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P2, N=100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2023

P2, N=12, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Sep 2025

P2, N=50, Not yet recruiting, University College, London | Trial completion date: Dec 2027 --> Oct 2028 | Initiation date: Nov 2023 --> Apr 2024 | Trial primary completion date: Nov 2027 --> Oct 2028

P2, N=100, Not yet recruiting, AstraZeneca | Trial completion date: May 2028 --> Feb 2029 | Trial primary completion date: May 2028 --> Feb 2029

P1/2, N=30, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2 | N=18 --> 30

The combined strength of long and short-read sequencing is apparent, where the high-precision junctional mapping complements and split paired-end reads. The potential is emphasized by the flexible single-sample genomic data acquisition of ONT with the high resolution of allelic imbalances using Illumina short-read sequencing.

P1/2, N=7, Terminated, AstraZeneca | N=50 --> 7 | Trial completion date: May 2025 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Oct 2024 --> Aug 2023; Due to safety reasons.

P1, N=18, Not yet recruiting, Chinese PLA General Hospital

P2, N=100, Not yet recruiting, Academic and Community Cancer Research United | Initiation date: Jul 2023 --> Nov 2023

P2, N=30, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=272 --> 30 | Trial completion date: Dec 2024 --> Dec 2023 | Trial primary completion date: Dec 2024 --> Dec 2023

P2, N=100, Not yet recruiting, AstraZeneca

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2025

P1/2, N=38, Recruiting, Chinese PLA General Hospital | Initiation date: Dec 2022 --> Jun 2023

P2, N=50, Not yet recruiting, University College, London | Trial completion date: Apr 2027 --> Dec 2027 | Initiation date: Mar 2023 --> Nov 2023 | Trial primary completion date: Mar 2027 --> Nov 2027

At the clinical level, mutated NOTCH genes are associated with aggressive features in MCL, such as the blastoid and pleomorphic variants, a shorter response to treatment, and inferior survival. In this article, we explore in detail the role of NOTCH signaling in MCL biology and the ongoing efforts toward targeted therapeutic interventions.

P2, N=100, Not yet recruiting, Academic and Community Cancer Research United

P3, N=635, Active, not recruiting, Acerta Pharma BV | Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Oct 2025 | Trial primary completion date: Apr 2023 --> Oct 2025

P2, N=272, Recruiting, AstraZeneca | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Dec 2024

We suggest that cytogenetic and iFISH analyses are complementary and use of DSP30+IL-2 is effective .in CLL. Decreased expression of hsa-miR-16-1 is remarkable.

P3, N=546, Recruiting, Acerta Pharma BV | Trial completion date: Apr 2023 --> Feb 2024

Despite the low number of patients treated with an MO approach, this study highlights the strengths and weakness of a molecular-targeted approach for the treatment of multiple myeloma. Widespread biomolecular techniques and improvement of precision medicine treatment algorithms could improve selection for precision medicine in myeloma.

P1/2, N=105, Active, not recruiting, AstraZeneca | Trial primary completion date: Jun 2022 --> Dec 2022

Moreover, the ISM-FISH showed a positive concordance of 96.6% and negative concordance of 98.8% with standard DC-FISH examining 1000 interphase cells. In conclusion, the ISM-FISH is a rapid and reliable diagnostic tool for the simultaneous examination of three critically important IGH translocations, which may promote risk-adapted individualized therapy in MM.

P2, N=12, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting | N=27 --> 12

P1/2, N=50, Recruiting, AstraZeneca | Trial primary completion date: May 2025 --> Oct 2024

LG-MCL show an immunohistochemical profile corresponding to the classical profile of MCL. Overexpression of molecules for target therapies was found in all cases (CD20 for rituximab, BCL2 for Bruton-kinase-inhibitors and CD19 for CAR-T cell therapy). The removal of the GL can potentially drive to severe complications, even if aimed to confirm diagnosis. Therefore, the choice between GL-biopsy and exstirpation should be carefully evaluated, especially in cases of suspected lymphoma.

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P1/2, N=50, Recruiting, AstraZeneca | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: Nov 2024 --> May 2025

P2, N=50, Not yet recruiting, University College, London